AIGH Capital Management LLC Makes New Investment in Zevra Therapeutics, Inc. $ZVRA

AIGH Capital Management LLC purchased a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 1,200,000 shares of the company’s stock, valued at approximately $11,184,000. Zevra Therapeutics makes up approximately 1.5% of AIGH Capital Management LLC’s investment portfolio, making the stock its 18th biggest position.

Several other hedge funds also recently modified their holdings of the company. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new stake in shares of Zevra Therapeutics in the 4th quarter worth $53,000. Russell Investments Group Ltd. boosted its stake in Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after buying an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after buying an additional 8,552 shares in the last quarter. Creative Planning acquired a new position in Zevra Therapeutics during the second quarter worth about $92,000. Finally, Qube Research & Technologies Ltd acquired a new position in Zevra Therapeutics during the second quarter worth about $99,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ZVRA. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a report on Tuesday, June 9th. Citizens Jmp lifted their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “market outperform” rating in a research note on Tuesday, June 9th. Wall Street Zen downgraded shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Maxim Group boosted their price objective on Zevra Therapeutics from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Finally, BTIG Research reaffirmed a “buy” rating and set a $27.00 price objective (up from $23.00) on shares of Zevra Therapeutics in a research note on Tuesday, June 9th. Nine analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Zevra Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $29.29.

Zevra Therapeutics Stock Up 2.1%

Shares of NASDAQ:ZVRA opened at $14.75 on Thursday. The company’s fifty day moving average is $11.95 and its two-hundred day moving average is $10.15. Zevra Therapeutics, Inc. has a 12-month low of $7.16 and a 12-month high of $15.04. The company has a market cap of $872.02 million, a P/E ratio of 7.41 and a beta of 0.85.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. The company had revenue of $36.22 million during the quarter, compared to analyst estimates of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. Equities research analysts anticipate that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.